InterCure (INCR) announced it has entered into a definitive Share Purchase Agreement and a Collaboration Agreement with Cannasoul R&D. The Share Purchase Agreement provides InterCure with a 28% ownership position in Cannasoul on a fully diluted basis and an exclusive path to increase its holdings to 51% within two years, while the Collaboration Agreement formalizes a partnership in research, development, and commercialization of evidence-based cannabis therapeutics.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCR:
- Gold tops $4,000, SoftBank buys robotics unit: Morning Buzz
- InterCure Announces Strong First Half 2025 Results Amid Strategic Expansion
- InterCure reports 1H revenue NIS 130M vs. NIS 126M last year
- InterCure Acquires ISHI to Expand U.S. Cannabis Market Reach
- InterCure announces acquisition of ISHI for 4.92M ordinary shares